Donepezil for vascular cognitive impairment

Cochrane Database of Systematic Reviews

Volumn 2010, Issue 1, 2004, Pages

  Malouf, Reem ^a   Birks, Jacqueline ^b  

^a Cochrane Dementia and Cognitive Improvement Group ^*  (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; INDAN DERIVATIVE; NOOTROPIC AGENT; PIPERIDINE DERIVATIVE;

CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; DAILY LIFE ACTIVITY; HUMAN; META ANALYSIS; MULTIINFARCT DEMENTIA; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ACTIVITIES OF DAILY LIVING; COGNITION DISORDERS; DEMENTIA, VASCULAR; HUMANS; INDANS; NOOTROPIC AGENTS; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS;

EID: 2942720598     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004395.pub2     Document Type: Review

References (72)

1. Anon. Efficacy and Tolerability of donepezil in vascular dementia: positive results of a 24-week, multicentre, international, randomized, placebo-controlled clinical trial. pre-publication report 2002.
2. Bayer A, Pratt RD, Kumar D. A comparison of the cognitive benefits of donepezil in patients with cortical and subcortical vascular dementia. 8th Congress of the European Federation of the Neurological Sciences. Paris, France. September 4-7, 2004. 2004.
3. Black S, RomanG, Geldmacher D, Salloway S, Hecker J, Burns A, Perdomo C, Kumar D, Pratt R, the Donepezil 307 vascular Dementia Study Group. Efficacy and tolerability of donepezil in vascular dementia positive results of a 24-week multicenter internationl randomized placebo controlled trial. Stroke 2003;43:2323-32.
4. Doody R, Pratt R, Posner H. Vascular dementia patients who receive donepezil treatment for 12 to 18 months maintain cognitive benefits. NeuroBiology of Aging 2004;25(S2):469.
5. Geldmacher DS, Pratt PD, Perdomo CA. Donepezil slows functional deterioration in patients with vascular dementia. European Journal of Neurology 2002;9(suppl 2):35.
6. Pratt RD. Patient populations in clinical trials of the efficacy and tolerability of donepezil in patients with vascular dementia. Journal of the Neurological Sciences 2002;203-204:57-65.
7. Pratt RD, Perdomo CA, The Donepezil 307 VAD Study Group. Donepezil improves cognition in patients with vascular dementia results from study 307 a 24 week randomized double blind placebo controlled trial. Springfield Conference 2002 The International Symposium on Advances in Alzheimer Therapy, Geneva. 2002:233.
8. Pratt RD, Perdomo CA, The Donepezil 307 and 308 VaD Study Groups. Population Characteristics and pattern of cognitive decline in patients with vascular dementia enrolled in two 24-week, randomized,double-blind, placebo-controlled trials. The 7th International Geneva Springfield Symposium on Advances in Alzheimer therapy. 2002 Apr 3-6:234.
9. Pratt RD, Perdomo CA, and the donepezil VaD 307 and 308 study groups. Donepezil-treated patients with probable vascular dementia demonstrate cognitive benefits. Annals of the New York Academy of Sciences 2002;977:513-522.
10. Salloway S, Pratt R, Posner H, Kumar D. Vascular dementia patients who receive donepezil treatment for 12 to 18 months maintain cognitive benefits. 8th Congress of the European Federation of the Neurological Sciences, Paris, France. September 4-7, 2004. Paris, France, 2004. 2004.
11. Salloway SP, Pratt RD, Perdomo CA. Donepezil is well tolerated in patients with vascular dementia: a comparison of tolerability in vascular dementia patients and Alzheimer's disease patients. European Journal of Neurology 2002;9(suppl 2):165-224.
12. Schindler R, Perdomo CA, Pratt RD. Donepezil provides significant benefits to patients with vascular dementia in their ability to perform everyday activities. 8th Congress of the European Federation of the Neurological Sciences. Paris, France. September 4-7, 2004. 2004.
13. Seltzer B, Perdomo CA, Pratt RD, Schindler R. Donepezil Provides Significant Benefits to Patients with Vascular Dementia in their Ability to Perform Everyday Activities. NeuroBiology of Aging 2004;25(S2):470.
14. Bayer A, Pratt RD, Kumar D. A comparison of the cognitive benefits of donepezil in patients with cortical and subcortical vascular dementia. 8th Congress of the European Federation of the Neurological Sciences. Paris, France. September 4-7, 2004. 2004.
15. Doody R, Pratt R, Posner H. Vascular dementia patients who receive donepezil treatment for 12 to 18 months maintain cognitive benefits. NeuroBiology of Aging 2004;25(S2):469.
16. Farlow Martin. Efficacy of donepezil in vascular dementia. Neurology 2003;61(4):429.
17. Pratt RD. Patient populations in clinical trials of the efficacy and tolerability of donepezil in patients with vascular dementia. Journal of the Neurological Sciences 2002;203-204:57-65.
18. Pratt RD, Perdomo CA, The Donepezil 307 and 308 VaD Study Groups. Population Characteristics and pattern of cognitive decline in patients with vascular dementia enrolled in two 24-week, randomized,double-blind, placebo-controlled trials. Springfield Conference 2002, The International Symposium on Advances in Alzheimer Therapy, Geneva. 2002, Apr 3-6:234.
19. Pratt RD, PerdomoCA, and the donepezil VaD 307 and 308 study groups. Donepezil-treated patients with probable vascular dementia demonstrate cognitive benefits. Annals of the New York Academy of Sciences 2002;977:513-522.
20. Salloway S, Pratt R, Posner H, Kumar D. Vascular dementia patients who receive donepezil treatment for 12 to 18 months maintain cognitive benefits. 8th Congress of the European Federation of the Neurological Sciences, Paris, France. September 4-7, 2004. Paris, France, 2004. 2004.
21. Salloway S, Pratt RD, Perdomo CA, The Donepezil 308 Study Group. Donepezil treated patients with vascular dementia demonstrated cognitive and global benefits: results from Study 308, a 24-week randomized double-blind, placebo-controlled trial. The 8th International Conference on Alzheiner's Disease and Related Disoreders, July 20-25, Stockholm, Sweden. 2002:Abstract No 219.
22. Salloway SP, Pratt RD, Perdomo CA. Donepezil is well tolerated in patients with vascular dementia: a comparison of tolerability in vascular dementia patients and Alzheimer's disease patients. European Journal of Neurology 2002;9(suppl 2):165-224.
23. Schindler R, Perdomo CA, Pratt RD. Donepezil provides significant benefits to patients with vascular dementia in their ability to perform everyday activities. 8th Congress of the European Federation of the Neurological Sciences. Paris, France. September 4-7, 2004. 2004.
24. Seltzer B, Perdomo CA, Pratt RD, Schindler R. Donepezil Provides Significant Benefits to Patients with Vascular Dementia in their Ability to Perform Everyday Activities. NeuroBiology of Aging 2004;25(S2):470.
25. Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, Kertesz A, Pratt RD, Donepezil 308 study. Donepezil in vascular dementia a randomized placebo controlled study. Neurology 2003;61(4):479-86.
26. Meyer JS, Chowdhury MH, Xu G, Li YS, Quach M. Donepezil treatment of vascular dementia. Annals of the New York Academy of Sciences 2002;977:482-6.
27. Rossor MN. A 30 week open-label evaluation of a new agent in patients with dementia associated with cerebrovascular disease. National Research Register 2003.
28. Shua-Haim JR, Shua-Haim Vered, Comsti E, Ross JS. Donepezil (Aricept R) treatment of multi infarct dementia the caregivers and clinical impression. American Journal of Alzheimer's Disease 2000;15(4):201-11.
29. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington DC: American Psychiatric Association, 1944.
30. Berg L. Clinical dementia rating (CDR). Psychopharmacology Bulletin 1988;24(4):637-39.
31. Bowen DM, Smith CB, White P, Davison AN. Neurotransmitter related enzymes and indices of hypoxia in senile dementia and other abiotrophies 6-Davis P, Malony AJF. 1976. Selective loss of central cholinergic neurons in alzheimer's disease. Lancet 1403. Brain 1976;99:459-96.
32. Brust JC. Vascular dementia is overdiagnosed. Achives of Neurology 1988;45(7):799-801.
33. Chui H, Victoroff J, Margolin D. Criteria for the diagnosis of ischaemic vascular dementia proposed by the state of California Alzheimer's Disease Diagnostic and Treatment centeres. Neurology 1992;42:473-80.
34. Crow TJ, Grove-White IG. An analysis of the learning defict following hyoscine administration to man. British Journal of Pharmacology 1973;49:322-7.
35. Davis P, Malony AJF. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976;ii:1403.
36. Dawbarn D, Shelly JA. Neurobiology of Alzheimer's disease. Second Edition. Oxford: Oxford University Press, 2001.
37. Desmond DW, Tatemichi TK, Paik M, Stern Y. Risk factors for cerebrovascualr disease as correlates of cognitive function in a stroke free cohort. Archives of Neurology 1993;50(2):162-66.
38. Ebly EM, Hogan DB, Parhad IM. Cognitive impairment in the non demented elderly result from the Canadian study of health and aging. Archiver of Neurology 1995;52:612-19.
39. Folstein MF, Folstein SE, McHugh PR. Mini-mental state a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975;12:189-98.
40. Gearing M, Mirra SS, Hedreen JC, Sumi SM, Hansen LA, Heyman A. The Consortium to establish a registry for Alzheimer's disease (CERAD) Part X neuropathology confirmation of the clinical diagnosis of Alzheimer's disease. Neurology 1995;45(3):461-66.
41. Gottfries CG, Blennow K, Karlsson I, Wallin A. The neurochemistry of vascular dementia. Dementia 1994;5:163-7.
42. Graham JE, Rockwood K, Beattie BL, et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet 1997;349:1793-96.
43. Hachinski VC, Iliff LD, Zilhka E, et al. Cerebral blood flow in dementia. Archives of Neurology 1975;32:632-7.
44. Hachinski VC. Preventable senility a call for action against the vascular dementias. Lancet 1992;340:645-8.
45. Hebert R, Brayne C. Epidemiology of vascular dementia. Neuroepidemiology 1995;14(5):240-57.
46. Heyman A, Fillenbaum GG, Welsh-Bohmer KA. Cerebral infarction in patients with autopsy proven Alzheimer's disease CERAD part XVIII. Neurology 1998;51:159-62.
47. Hofman A, Rocca WA, Brayne C. The prevalence of dementia in Europe a collaborative study of 1980-1990 findings Eurodem prevalence research group. International of Journal of Epidemiology 1991;20(3):736-48.
48. Jorm AF. Cross national comparisons of the occurrence of Alzheimer's disease and vascular dementias. European Archive of Psychaitry and Clinical neuroscience 1991;240:218-222.
49. Joynt RJ. Vascular dementia too or too little. Archives of Neurology 1988;45(7):801.
50. Knopman DS, Knapp MJ, Gracon SI, et al. The clinician interview based impression (CIBI) a clinician's global change rating scale in Alzheimer's disease. Journal of Neurology 1994;44:2315-21.
51. Mann DMA, Yates PO, Marcyniuk B. The nucleus basalis of Meynert in multi infarct vascular dementia. Mann DMA, Yates PO, Marcyniuk B. The nucleus basalis of Meynert in multi infarct vascular dementia Acta Neuropathology;71:332-7.
52. Meyer JS, Muramatsu K, Mortel KF, Obara K, Shirai T. Procpective CT confirms differences between vascular and Alzheimer's dementia. Stroke 1995;269(5):735-42.
53. Meyer JS, Chowdhury MH, Xu G, LI YS, Quach M. Donepezil treatment of vascular dementia. Annals of the New York Academy of Sciences 2002;977:482-6.
54. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, Pratt RD. A 1 year placebo controlled preservation of function survival study of donepezil in AD patients. Neurology 2001;57:481-88.
55. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 2001;357:169-75.
56. Mulrow CD, Oxman AD. Cochrane Collaboration Handbook. Oxford: Cochrane Collaboration, 1997.
57. O'Brien MD. How does cerebrovascular disease cause dementia. De Mentia 1994;5(3-4):133-36.
58. O'Brien JT, Ballard CG. Drugs for Alzheimer's disease. British Medical Journal 2001;323:123-4.
59. O'Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, Boeler JV, Ballard C, DeCarli C, Gorelick PB, Rockwood K, et al. Vascular cognitive impairment. The Lancet Neurology 2003;2:89-98.
60. Perry EK, Gibson PH, Blessed G ee. Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activites in necropsy brain tissue. Journal of Neurological Science 1977;34:247-65.
61. Rockwood K, Ebly E, Hachinski V, Hogan D. Presence and treatment of vascular risk factors in patients with vascular cognitive impairment. Archives of Neurology 1997;54(1):33-9.
62. Rockwood K, Wentzel C, Hachinski V, Hogan DB, MacKnight C, McDowell I. Prevalence and outcomes of vascular cognitive impairment. Neurology 2000;54:447-51.
63. Roman G, Tatemichi T, Erkinjuntti T. Vascular dementia diagnostic criteria for research studies. Neurology 1993;43:250-60.
64. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. American Journal of Psychiatry 1984;141:1356-64.
65. Schwarz RD, Callahan Mj, Coughenour LL. Milameline (CI-979/RU35926) a muscarinic receptor agonist with cognition activating properties biochemical and in vivo characterization. Journal of Pharmacol Expermental Therapy 1999;291:812-22.
66. Snowdon DA, Greiner LH, Mortimer JA. Brain infarction and the clinical expresion of Alzheimer's disease the nun study. Journal of the American Medical Association 1997;277:813-17.
67. Stewart R, Liolitsa D. Type 2 diabetes mellitus cognitive impairment and dementia. Diabetes Med 1999;16:93-112.
68. Toghi H, Abe T, Kimura M. Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarcts types as copared with Alzheimer's type dementia. Journal of Neural Transmission 1996;103:1211-20.
69. Ueda K, Kawano H, Hasuo Y, Fujishima M. Prevalence and etiology of dementia in a Japanese community. Stroke 1992;23(6):798-803.
70. World Health Organization. International Statistic Classification of Disease and Related Health Problems. 10th Edition. Geneva: World Health organiazation, 1992:25-31.
71. Zhang MY, Katzman R, Salmon D. The prevalence of dementia and Alzheimer's disease in Shanghai China impact of age gender and education. Annals of Neurology 1990;27:428-37.
72. Zhang W, Edvinsson L, Lee TJF. Mechanism of nicotine induced relaxation in the porcine basilar artery. Journal of Pharmacology Expermental Therapy 1998;284:790-7.